CPRX
CATALYST PHARMACEUTICALS, INC.
Nasdaq: CPRX · Coral Gables, FL · Healthcare
$31.34+0.06 (+0.19%)Closed
Market Cap$3.83B
Cash$755.9Mmost recent
Runwayprofitable
P/E (TTM)18.7EPS $1.68
52-Wk Range$19.13 – $31.34
Avg Volume1.6M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$31.34+100.5%
Pipeline

Drug candidates sponsored by CATALYST PHARMACEUTICALS · ClinicalTrials.gov

6 drugs · 13 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 2Vigabatrin
Cocaine Addiction+1 more
Completed
2012-10past
2
Phase 3Amifampridine Phosphate
Lambert Eaton Myasthenic Syndrome+8 more
Completed
2022-08-05past
7
Phase 2CPP-109 vigabatrin
Methamphetamine Dependence
Terminated
2009-06past
1
Phase 2Amifampridine Phosphate 10 MG Oral Tablet
Spinal Muscular Atrophy Type 3
Terminated
2021-09-13past
1
Phase 1CPP-115
Cocaine Dependency
Completed
2012-06past
1
N/AVamorolone
Duchenne Muscular Dystrophy
Recruiting
2032-02
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for CPRX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.